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2Translational Statement23
Penile Cancer (PeCa) is rare in the developed world, but represents a global health problem,24
with an incidence of up to 8.3:100,00 in developing nations. The most important predictive25
factor of an unfavourable prognosis in PeCa is the presence of regional inguinal lymph node26
involvement. Currently, no molecular markers exist that can accurately predict the presence of27
lymph node metastases. Using genome wide DNA methylation profiling, we defined the28
epigenetic alterations involved in PeCa and validated an epigenetic signature which is predictive29
of lymph node metastasis. HPV represents a major oncogenic driver in PeCa, we identify HPV30
induced epigenetic alterations, from these we define an epigenetic signature that is predictive of31
survival across multiple HPV driven cancers. The identification of epigenetic biomarkers of32
metastasis and survival may play a significant role in improving the management, treatment and33
survival of penile cancer and also other HPV driven cancers.34
35
Abstract36
Purpose : Penile cancer is a rare malignancy in the developed world, with just over 1600 new37
cases diagnosed in the USA per year, however, the incidence is much higher in developing38
countries. Although HPV is known to contribute to tumourigenesis, little is known about the39
genetic or epigenetic alterations defining penile cancer (PeCa).40
Experimental Design: Using high-density genome-wide methylation arrays we have identified41
epigenetic alterations associated with PeCa. Q-MSP was used to validate lymph node metastasis42
markers in 50 cases. 446 HNSCC and CESCC (head and neck squamous cell carcinoma and43
3cervical squamous cell carcinoma) samples were used to validate HPV associated epigenetic44
alterations.45
Results: We defined 6933 methylation variable positions (MVPs) between normal and tumour46
tissue, which include 997 hypermethylated differentially methylated regions associated with47
tumour supressor genes including CDO1, AR1 and WT1. Analysis of PeCa tumours identified a 448
gene epi-signature which accurately predicted lymph node metastasis in an independent cohort49
(AUC of 89%). Finally, we explored the epigenetic alterations associated with PeCa HPV infection50
and defined a 30 loci lineage independent HPV specific epi-signature which predicts HPV status51
and survival in independent HNSCC, CESC cohorts. Epi-signature negative patients have a52
significantly worse overall survival (HNSCC p=0.00073, CI 0.021-0.78, CESC p= 0.0094, HR=3.91,53
95% CI =0.13-0.78), HPV epi-signature is a better predictor of survival than HPV status alone.54
Conclusion: These data demonstrate for the first time genome-wide epigenetic events involved55
in an aggressive penile cancer phenotype and define the epigenetic alterations common across56
multiple HPV driven malignancies.57
Introduction58
Penile Cancer (PeCa) is relatively rare in the developed world, but represents a global health59
problem, showing high prevalence and posing significant morbidity and mortality in developing60
countries (1, 2). The age standardised incidence of PeCa is 0.3-1.0 per 100,000 men in European61
countries and the United States, equating to approximately 1600 new cases per annum in the62
USA (2). In contrast, the incidence in developing nations varies from 3 to 8.3 per 100,000 (3, 4).63
The presence of inguinal lymph node involvement is at present the most important prognostic64
indicator of unfavourable prognosis in penile cancer (5). Although, histopathological factors65
4including tumour subtype, grade, stage and the presence of lymphovascular and perineural66
invasion are useful predictors of inguinal lymph node metastases, they are still not accurate and67
if used exclusively would lead to overtreatment of a significant proportion of patients. The68
aetiology of PeCa, is multifactorial with smoking, phimosis, poor personal hygiene and low69
socioeconomic status all being risk factors for tumour development (6). Additionally, there is70
strong evidence linking development of PeCa to infection with high risk HPV (HPV 16, 18),71
suggesting that HPV plays a significant role in the pathogenesis of at least a subset of cases. High72
risk HPV infection is transformative in other tumour types including cervical squamous cell73
carcinoma and head and neck squamous cell carcinoma (CESC and HNSCC respectively) (7, 8).74
Contrary to cervical cancers, which appear to be almost exclusively (>90%) driven by HPV, only a75
proportion of penile, vulvar, anal, and oropharyngeal cancers appear to be HPV driven (9, 10).76
Interestingly, despite the clear oncogenic effects of HPV infection, HPV positivity appears to77
confer a survival benefit, this is particularly true for HNSCC, and also appears to be for PeCa,78
although as yet only limited data is available (11).79
Changes in DNA methylation play a key role in malignant transformation, leading to the silencing80
of tumor-suppressor genes and overexpression of oncogenes(12). The ontogenic plasticity of81
DNA methylation makes epigenetic changes ideal biomarkers for diagnosis or as predictive and82
prognostic markers in cancer. However, little is known about the molecular genetics or83
epigenetics driving the development and progression of PeCa. Aberrant methylation of a84
handful of candidate genes has previously been identified, including CDKN2A and RASSF1A (13-85
16). Recently, epigenetic changes in both host and virus epigenomes have been reported in86
other HPV induced cancers (17-20). To date no substantial genome wide analysis has been87
performed in penile cancer and linkage between viral subtypes has not been elucidated. We88
have therefore sought to define the epigenetic alterations associated with penile carcinogenesis89
5including a subset of cases associated with high risk HPV infection. Using high density genome-90
wide methylation array on a panel of PeCa and matched normal tissue we have annotated91
epigenetic alterations which define PeCa d, we also interrogated these data to reveal epigenetic92
changes associated with disease progression and HPV infection.93
Materials and Methods94
Ethics Approval95
Ethics approval for this study was granted by the University College London (UCL) / University96
College London Hospital (UCLH) BioBank for Health and Human Disease (NC06.11). Informed97
consent was obtained.98
Patient Samples and Clinical Data99
Thirty-eight fresh penile cancers and 11 matched normal tissue samples (stored in RNAlater)100
from the UCL/UCLH Urology Biobank, and 50 formalin-fixed paraffin-embedded (FFPE) tissue101
blocks from the Department of Pathology (UCLH) with confirmed histopathological and clinical102
diagnosis of PeCa and with > 80% tumour cellularity were included and analysed. Normal103
samples taken adjacent from tumour tissue and confirmed to be histologically normal in104
pathological review (Supplementary Table 1 and 2).105
DNA Extraction106
DNA was extracted from RNA-later preserved frozen tissue using the QIAmp DNA MiniKit107
(Qiagen), and FFPE tissue using the QIAmp DNA FFPE Tissue Kit (Qiagen) according the108
manufacturer’s instructions.109
6HPV Assessment110
All samples were assessed for the presence of low risk HPV 6 and 11 and high risk HPV 16, 18111
and 31 viral DNA by qPCR with primers specific for each genotype (Supplementary Table 2A).112
The reference genes GAPDH and ACTB was used to normalise DNA input and calculate the113
number of HPV genomic copies present. HPV qPCR was carried out as previously described be114
Lechner et al (22). HPV type data for CESC and HNSCC TCGA samples were take from Tang et al.,115
and based the expression of viral genes in RNA-seq data (21).116
Methylation Analysis117
500 ng of DNA from 38 tumour and 11 matched normal RNAlater-preserved samples from PeCa118
patients were bisulphite converted and hybridised to the Infinium 450K Human Methylation119
array, and processed in accordance with the manufacturer's recommendations. DNA bisulphite120
conversion was carried out using the EZ DNA Methylation kit (Zymo Research) as per121
manufacturer’s instructions. Samples were processed in a single batch. R statistical software122
(version 2.14.0 (22)) was used for the subsequent data analysis. The ChAMP pipeline was used123
to extract and analyse data from iDat files, samples were normalised using BMIQ (23). Raw β124
values (methylation value) were subjected to a stringent quality-control analysis as follows:125
samples showing reduced coverage were removed and only probes with detection levels above126
background across all samples were retained (detection P < 0.01). DMRs (differentially127
methylated regions) were called using the Probe Lasso algorithm (implemented in ChAMP128
package; see Morris et al) with default parameters with the exception of applying a minimum129
DMR size of 100bp. As a result, all DMRs identified have a minimum of 3 significant probes, are130
at least 1Kb from a neighbouring DMR, and have a minimum size of 100bp. Maximum DMR size131
is effectively unbounded but is dependent the genomic separation between contiguous CpG132
7probes, which itself is contingent on the local underlying genomic and epigenomic features with133
larger DMRs more likely to occur in probe-poor regions(Butcher et al., in press,(23))134
135
The statistical significance of MVP enrichment in genomic and epigenomic features was136
calculated based on the random selection of equal numbers of probes (4935 for137
hypermethylated MVPs, 1998 hypomethylated MVPs), from the overall probe set (472,655138
probes) used in the analysis and repeated 10,000 times(24).139
140
Gene set enrichment analysis (GSEA) was used to assess if gene associated DMRs are141
overrepresented in a particular gene set. Gene sets, categorised by gene ontology, molecular142
pathways, chromosomal locations, or targets of regulatory motifs and miRNAs, were derived143
from the Molecular Signatures Database (MSigDB). Enrichment was assessed by comparing the144
number of genes associated with DMRs belonging to the gene set with those that are not145
members. The significance of the over-representation was then assessed by a Fisher’s146
exact test and adjusted for false discovery by the Benjamini Hochberg procedure. Genes147
containing multiple DMRs were counted only once in order to remove any bias in gene set148
enrichment.149
Motif analysis was performed using the MEME-ChIP tool of the MEME suite; parameters were150
set to default except for the number of repetitions (set to ‘Any number of repetitions’), motif151
width (min=4, max=15), and maximum number of motifs to find set to 20 (25).152
8Validation of methylation153
Aberrant methylation was validated in the external cohort using Methylation Specific qPCR154
(MSP) (Supplementary Table 2).. Genomic DNA from FFPE samples was bisulphite converted as155
above. 10 ng of converted DNA was subjected to MSP. Briefly, all reactions were carried out in a156
13 L reaction volume containing 6.5 L 2X SYBR Green reaction buffer, 0.3 mol/L forward157
primer and 0.3 mol/L reverse primer with 1 ng genomic DNA (RNAlater-preserved) or 10ng for158
FFPE samples. Reactions were run on an ABI 7300 RealTime PCR machine, denaturation for 10159
minute at 95OC, with 40 cycles of 95 OC for 15 seconds and 60 OC for 60 seconds. All reactions160
were performed in triplicate. Sensitivity and specificity of all reactions was assessed using spiked161
dilutions of fully methylated DNA. The methylation state of individual samples was determined162
using a standard curve with a range of control methylation states (0% to 100%). The absolute163
methylation was subsequently used to determine the association with lymph node metastasis.164
Integration of obtained methylation data with publicly available methylation data165
HNSCC data166
R statistical software v2.15.1 [35] was used for pre-processing of data and for classic167
multidimensional scaling (MDS) using principal components analysis (PCA). HPV specific168
epigenetic signature and prediction of HPV infection was determined using the shrunken169
centroid method implemented through the pamr bioconductor package. Survival analysis was170
carried using the bioconductor package; Survival (26). MDS was used to visualize HPV+ve and171
HPV-ve PeCa methylation signatures within methylation datasets obtained from an HPV-induced172
head and neck squamous cell carcinomas ((20) GEO accession numbers: GSE38266, GSE38268,173
GSE38270 and GSE38271, and TCGA samples from HNSCC(27) and CESC(28). Raw iDAT files were174
processed and normalised in line with in house data as above.175
9176
RT-PCR177
RNA was extracted from tissue, determined by H&E staining of frozen sections to be tumour178
or normal tissue from the same individuals, using an RNeasy kit according to the manufacturer's179
instructions. RNA was quantified using a NanoDrop spectrophotomer and for each sample, 1 ug180
was reverse transcribed to cDNA in a 20 uL reaction using a Quantitect reverse transcription kit181
(QIAGEN) including a gDNA wipeout step. Completed reactions were diluted 10-fold with yeast182
tRNA 0.5 ug/mL and 2 ul were used for qPCR using Brilliant III SYBR Green UltraFast qPCR master183
mix (Agilent) and with primers at 500 nmol L-1 each in a final reaction volume of 10 uL.184
Standards (10^7-10^1 copies/rxn) were amplified together with samples in a Rotor-Gene Q185
(QIAGEN) using the following parameters: 95C for 3 minutes followed by 40 cycles of 95C for 5186
sec and 57C for 10 sec. Melt curve data were collected to confirm product identity. For all assays187
efficiency was >95%, and reactions were linear over 7 log and sensitive to at least 10 copies and188
a single PCR product of the correct size was observed on a 2% agarose gel. Copy numbers/rxn189
were derived from the standard curves and normalized using the normalization factor for the190
three most stable reference genes identified by geNorm software: HPRT1, SDHA, YWHAZ. Data191
were analyzed using a paired Student's t-test with alpha at 0.05192
Results193
Tumour specific methylation events194
To investigate whether penile tumours are epigenetically distinct from normal tissue, we195
performed genome-wide DNA methylation profiling using the 450k Illumina Infinium platform196
(29) to interrogate the methylation state of over 485,000 cytosine residues.197
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Unsupervised hierarchical clustering of beta values (methylation score) revealed three distinct198
clusters based on histological phenotype (Figure 1A). Clustering of the most variable probes199
(n=500) separated samples based on histopathology confirming that PeCa and normal penile200
tissue are epigenetically distinct, and pointing to a hypermethylation phenotype associated with201
malignant transformation (Figure 1B).202
Supervised analysis, using a Wilcoxon rank-sum test to assign directionality, was used to identify203
MVPs (methylation variable positions) between PeCa versus normal tissue. MVPs were selected204
on the basis of statistical significance (Wilcoxon P-value>0.001), an additional filter of205
Δβ>0.30(+/-) was applied to compensate for not taking into account the absolute difference in 206 
methylation between the groups. The cut-off is empirically defined to result in a false discovery207
rate (FDR) of <2%. This allowed us to reduce our candidate loci to those with largest methylation208
differences and therefore greatest potential for functional effect. A total of 6933 MVPs met209
these requirements (4935 Hyper MVPs, 1998 Hypo MVPs), hierarchical clustering of the samples210
yielded three clusters 1) Normal, 2) Node positive and 3) Node negative (Figure 1C).211
There is a clear hypermethylation profile associated with the cancer phenotype (Figure 1C),212
with over 71% of MVPs being hypermethylated in tumour tissue compared with matched213
normal tissue (Supplementary Figure 1). Mapping of the MVPs to gene features revealed a214
significant (random resampling p <0.0001) enrichment of hypermethylated CpG islands (CpGI),215
44% enrichment (Figure 2A,B). To assess the potential functional impact of CpGI methylation on216
gene expression we tested the association with MVPs in either promoter associated or non-217
promoter associated CpGIs. This showed a enrichment (p<0.0001) of MVPs in promoter218
associated CpGIs, and is further supported by the enrichment (p<0.0001) of MVPs in regulatory219
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regions including transcription start sites (TSS200), 1st exons, and 5’ UTRs, which show220
enrichments of 8%, 7% and 4% respectively (Figure 2A,B).221
Analysis of hypomethylated MVPs showed enrichment (p=0.00101, 14%) of intergenic regions222
(IGR) (Figure 2C,D), potentially pointing to hypomethylation of repeats regions. This is confirmed223
by the enrichment of loci within ALU and SINE1 repeat elements.224
As single MVPs are less likely to have functional effect on gene expression, we next sought to225
amalgamate individual MVPs into Differentially Methylated Regions (DMRs). The analysis226
defined 1255 significant DMRs (p<0.001) associated with the malignant phenotype (997 hyper227
DMRs and 258 hypo DMRs). The DMRs were associated with 367 genes, CpGIs were the228
predominant genomic feature associated DMRs.229
230
Gene set enrichment analysis231
GO analysis of genes associated with DMRs identified genes involved in DNA binding232
(GO:0003677), Signal Transduction (GO:0007165) and Receptor activity (GO:0004872) pathways.233
We also performed gene set enrichment analysis, assigning MVPs to their closest gene, to assess234
whether specific classes of genes are enriched. Interrogation of the PeCa-associated235
hypermethylated genes showed significant enrichment (P=0.000106) of genes which are targets236
of the PRC2 complex, including TBX5, GATA4, CDH7 and SOX14. Motif analysis of PRC2 target237
DMRs showed enrichment for PBX1, KLF4 and HIF1A transcription factor binding sites.238
Interestingly, we also see an increase in the expression of PRC2 complex members SUZ12 and239
EZH2 in tumours compared to normal tissue (Supplementary Figure 2).240
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The high rate of CpGI methylation would suggest the potential for frequent inactivation of241
tumour suppressor genes (TSGs). We therefore compared genes associated with both MVPs and242
DMRs with a list of 712 known TSGs. This revealed the enrichment of hyper-MVPs in TSGs243
(p=0.0019), with 52 TSGs showing CpGI hypermethylation, these include RASSF2, WT1 & CDO1.244
We also identified aberrant methylation of several potential therapeutic targets, including245
tyrosine kinases, EPHA5, EPHA6 along with FLT1 (VEGFR1), FLT3 and FLT4 (VEGFR3), and246
aberrant methylation of the androgen receptor (AR) and programmed cell death receptor 1247
(PDCD1) the gene which encodes PD1, highlighting potential therapeutic targets for the248
treatment of PeCa (Supplementary Figure 3, Supplementary Figure 4A-B).249
To confirm the functional relevance of methylation we assessed the expression of two candidate250
genes (CDO1 and AR) in an independent cohort of matched PeCa and normal tissues. This251
showed a significant reduction of expression in PeCa compared with matched normal tissue252
(Supplementary Figure 4C-D).253
254
Epigenetic markers of lymph node metastasis.255
Unsupervised clustering of the top 500 most variable (tumour only) probes was performed to256
assess the association of aberrant epigenetic events with pathological factors. This defined two257
clusters (Figure 3A), which showed a significant correlation with lymph node status (P=000017),258
with a hypermethylated lymph node positive cluster and hypomethylated lymph node negative259
cluster. No correlation was found between these clusters and tumour grade or stage (P>0.05).260
In order to more clearly define the epigenetic alterations associated with local metastatic spread261
we carried out a supervised analysis utilising all 48577 informative loci (Figure 3B). This defined262
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a small number of MVPs (n=112), which separate samples into two main groups, a263
hypomethylated lymph node positive group and a hypermethylated lymph node negative264
disease group. Analysis of the enriched MVPs in canonical gene features, shows enrichment of265
hypomethylated MVPs within CpGIs (P<0.0001), with 72% of MVPs located in CpGIs. These data266
suggest that CpGI hypermethylation is associated with lower metastatic potential.267
268
The ability to predict lymph node metastasis may have potential utility in the clinical269
management of patients by identifying which patients with clinically impalpable inguinal lymph270
nodes require an inguinal lymphadenectomy. To explore this we sought to define a minimal271
epigenetic signature, which could be used to predict lymph node metastasis. Using a shrunken272
centroids approach, we identified a minimum 54 CpG signature which in cross validation, could273
predict the lymphatic metastases with an accuracy of 93%. When individual MVPs were274
coalesced into potentially functional DMRs, we identified DMRs in four genes, HMX3, IRF4, FLI1275
and PPP2R5C, to be predictive of lymph node positive disease (Figure 4 A-B, Supplementary276
Figure 5). These DMRs were combined to define a final predictive methylation index for each277
sample (mean methylation state across DMRs). This predictive index reached an ROC of 98%278
(specificity 100%, sensitivity 92%,) (Supplementary Figure 5). We then tested the association of279
this gene panel in a validation cohort of a further 50 patients with FFPE DNA using qMSP for280
each DMR. In the validation cohort the predictive lymph node metastasis signature reached an281
AUC of 0.89 (specificity 80%, sensitivity 93%)(Figure 4C).282
Multivariable analysis showed this minimal signature to be an independent predictor of lymph283
node metastasis (P=0.0053), a surrogate for disease-specific survival, there was no significant284
association with age, stage or grade (p=1, p=0.98, p=0.76) in multivariable analysis.285
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286
Immunohistochemical analysis for FLI1 and IRF4 (available antibodies) was carried out on a287
tissue microarray containing the 50 PeCa tumours. Although we observe a reduction in protein288
expression in samples with corresponding hypermethylation, the relationship with lymph node289
metastasis was not statistically significant (Supplementary Figure 5B).290
HPV-driven tumourigenesis291
Unsupervised clustering points to the presence of a potential HPV related epigenetic component292
(Figure 5A). To define a HPV induced epigenetic signature we performed a supervised analysis293
and ranked probes using a Bayesian regularised t-statistics model. We identified a significant294
association between DNA methylation and HPV status, with 960 significant MVPs at an FDR of295
less than 0.01, and 5037 at an FDR of < 0.05. Of the 960 MVPs, the overwhelming majority (747,296
77%) were hypo-MVPs in HPV positive samples, compared with HPV negative, indicating that297
HPV infection is associated with widespread loss of DNA methylation (Figure 5A). Analysis of the298
canonical gene features in which these MVPs reside showed that over 67% are located with299
CpGI’s, shores and shelves, with a significant enrichment (p<0.001) of MVPs in CpGI shores.300
When individual MVPs were coalesced into potentially functional DMRs, we identified DMRs in301
several candidate genes including GRAMD4 and GPX5 (Figure 5B-C). GO analysis of analysis of302
genes associated with PeCa HPV DMRs identified genes involved in WNT signaling, DNA binding,303
Signal Transduction and Receptor activity pathways. They also showed significant overlap with304
genes shown to be up-regulated in nasopharyngeal tumours, which are also frequently driven by305
HPV. Motif analysis of PeCa HPV DMRs showed enrichment for TCF3, MAZ, JUN, PAX4 and MYC306
transcription factor binding sites.307
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Lineage independent HPV signature308
We sought to assess if the effect of HPV infection on DNA methylation is lineage dependent by309
evaluating the methylation state of PeCa HPV MVPs in HNSCC and CESC. Using all PeCa HPV310
MVPs we were able to accurately define HPV positive from HPV negative disease in 42 HNSCC311
(Data not shown). We subsequently identified the overlapping loci between these two data sets,312
in order to define a lineage independent HPV signature. Despite the apparent strong association313
of our PeCa HPV epigenetic signature across different tissue lineages, there is little overlap in314
epigenetically altered loci, with only 30 overlapping loci MVPs in both tissue types. Analysis of315
the methylation state of these loci reveals a distinct hypomethylated signature associated with316
HPV-positive disease (Data not shown). For cross validation we performed a shrunken centroid317
class prediction used the 30 MVPs and were able to accurately predict the HPV status of 27/28318
HPV positive and 57/58 HPV negative samples from the combined PeCa-HNSCC training cohort.319
We were also able to accurately predict the HPV status of a panel of HPV positive and HPV320
negative HNSCC cell lines (n=6) (Supplementary Figure 6).321
322
We subsequently applied this HPV epi-signature to an independent set of HNSCC (n=310) and323
CESC (n=136) samples. When applied to HNSCC the HPV epi-signature predicated 40 HPV324
positive and 290 HPV negative (Figure 6). When comparing those samples with a known HPV325
status this accurately predicted the HPV status of 299/310 HNSCC samples (4 false positives, 7326
false negatives), giving an overall misclassification rate of 3.5% (Figure 6A).327
When comparing the predicted HPV status of all 310 HNSCC compared with pathological328
features, there was a significant association with patient overall survival, with a 5-year survival329
for signature negative patients of 38% compared to 81% for signature positive patients330
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(p=0.00073, HR = 5.6, 95% CI 0.021-0.78) (Figure 6B) although not independent of HPV status.331
There was no significant association of our HPV epigenetic signature with stage, age or gender.332
We also assessed an independent cohort of 136 cervical cancer samples, using the same 30 loci333
HPV epi-signature 66% (90) were predicted to be signature positive compared to 34% (46)334
predicted to be signature negative. Epi-signature negative samples had a significantly (p=0.05)335
worse overall survival than signature positive samples, with a 5 year overall survival for336
signature positive patients of 77% compared to 50% for signature negative patients. Age337
(p=0052) and stage (p=0.035) were also significant in multivariate analysis.338
As >90% of CESCC are a result of HPV infection, using only those samples with a known HPV339
status (n=84) we compared the predicted and actual HPV status (Figure 6C). Of those 62 epi-340
signature positive samples 53 (85%) were HPV16 positive, compared to 9/62 (15%) which341
contained other high risk HPV subtypes, including HPV18. Of those epi-signature negative342
samples only 2 out of 22 (9%) contained HPV16, suggesting the possibility of a HPV16 specific343
epigenetic alteration signature. Of the 84 patients with a confirmed HPV genotype, 73 had344
confirmed outcome data. Signature positive patients had a significantly better overall survival345
than signature negative (Figure 6D) (p= 0.0094, HR=3.91, 95% CI =0.13-0.78 ) (adjusted for age,346
grade and stage). Despite correlating strongly with HPV genotype, the HPV epi-signature347
appears a stronger predictor of CESC patient survival than HPV genotype alone (p=0.07,348
HR=2.56, 95% CI=0.14129-1.083) (adjusted for age, grade and stage).349
Discussion350
Penile cancer is a rare disease in the developed world, however represents a significant source351
of patient morbidity and mortality in developing nations. The results reported here represent352
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the most comprehensive epigenetic study of penile squamous cell carcinoma to date and shed353
light on to the epigenetic alterations involved in penile cancer. Using high density genome-wide354
methylation arrays we have revealed distinct PeCa associated epigenetic signatures and define355
an epigenetic signature which can predict local lymph node metastasis, one of the most356
important prognostic indicators for PeCa survival, and, to our knowledge, this is the first study to357
demonstrate the existence of an HPV-mediated DNA-methylation signature in HPV positive358
PeCa.359
Previous studies have identified differentially methylated genes in PeCa(14, 15). These have360
been targeted studies in which candidate epigenetic regulated genes have been identified361
including RAS and THBS1. Using the Illumina Infinium Human Methylation arrays, we defined362
over 1,200 DMRs associated with the malignant phenotype and CIMP relating to 367 genes.363
Supervised analysis of PeCa versus normal tissue identified PeCa-associated hypermethylated364
genes with significant enrichment of genes which are targets of PRC2 complex, these include365
TBX5, GATA4, CDH7 and SOX14. Aberrant methylation of genes regulated by the PRC2 complex366
has been observed in many cancer types, including head and neck, cervical and prostate cancer367
but not previously in penile cancer. However, changes in the epigenetic regulation of PRC2368
target genes has been noted during the HPV16 transformation of normal foreskin keratinocytes,369
with HPV16 infection resulting in the increased EZH2 expression and decreased global370
H3K27me3 (30). Furthermore, we also see overexpression of the members of the PRC2 complex371
(EZH2 and SUZ12) in PeCas. This has been reported in other tumour types and shown to result in372
loss of PRC2 target gene expression(31). These data would suggest that deregulation [through373
either aberrant methylation, altered histone code or increased PRC2 complex expression] of374
PRC2 regulated genes is an essential part of the oncogenic transformation of both HPV and non-375
HPV related PeCa and warrants further investigation.376
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The hypermethylation of tumour suppressor genes (TSGs) is a key feature of tumourigenesis. To377
identify key TSGs regulated by methylation we compared with both MVP and DMR with a list of378
712 known TSGs. This included CDO1, which we also show to be differentially expressed379
between PeCa and normal tissue. The inactivation of CDO1 by DNA methylation has recently380
been implicated in many cancers including bladder, breast cancer colon and lung cancer (32-36).381
Cysteine deoxygenase 1 (CDO1) is integral to the biodegradation of toxic cysteine, and reduced382
CDO1 expression has been shown to increase cell proliferation in vitro, whereas over expression383
resulted in decreased tumour growth both in vitro and in vivo (33).384
We also identified aberrant methylation of several potential therapeutic targets, including the385
hypermethylation and epigenetic regulation of the androgen receptor (AR). The aberrant386
methylation of the AR is particularly intriguing. Increased AR signalling is important in387
hormonally driven tumours including prostate and breast cancers. Although it is assumed388
increased AR expression is oncogenic in hormonally driven cancers, it has recently been shown389
that loss of AR in hormone refractory prostate cancer results in the activation of STAT3 (37).390
STAT3 regulates gene involved in the control of cellular processes including proliferation,391
survival and immune responses (38). Persistent activation of STAT3 is oncogenic and has been392
implicated in the development of a wide variety of human malignancies including leukaemia and393
lymphoma and solid tumours including head and neck cancer, prostate, breast and colon394
cancers (39-41). Although still to be functionally validated, these data would suggest the395
potential for a pivotal role for loss of the androgen receptor in the development of penile396
cancer.397
The presence of metastatic disease in the inguinal lymph nodes is one of the most important398
prognostic factors in penile cancer (42). Occult nodal metastasis are present in 20 - 25% of cases399
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at presentation (43, 44) and inguinal lymph node dissection is largely directed by clinical400
examination and the histopathological features of the primary lesion. Due to the lack of401
biomarkers which can accurately identify or predict lymph node metastasis, all patients with402
≥T1G2 disease and impalpable inguinal lymph nodes undergo inguinal lymphadenectomy 403 
(removal of the inguinal lymph nodes), which is unnecessary in 75 - 80% of patients. Lymph404
node metastasis is an independent predictor of survival in penile cancer and therefore may be405
used as a surrogate disease-specific survival (45).406
Methylome analysis identified a distinct epigenetic signature associated with lymph node407
metastasis. This 122 CpG classifier, which in cross validation, could predict the lymphatic408
metastases with an accuracy of 93%. The majority of MVP were located within DMRs in 4 genes,409
HMX3, IRF4, FLI1 and PPP2R5C and DMR methylation was also predictive of lymph node positive410
disease. When combined as predictive methylation index for each sample, the predictive411
accuracy of this signature (90% methylation array and 89% for qMSP) to identify the presence of412
lymph node metastasis is at least comparable to if not better than the sensitivity of sentinel413
lymph node biopsy. We are currently assessing the feasibility of using the methylation state of414
these loci as biomarkers in ‘liquid’ biopsy, using plasma cell free DNA to detect metastasis415
specific methylation events.416
Finally, we also sought to understand the relationship between epigenetic alterations and HPV417
and clinical pathological factors. High risk HPV infection is a key oncogenic driver in several418
different tumour types, including, cervical cancer, head and neck squamous cell cancers along419
with PeCa. It is well documented in HNSCC and cervical cancers that HPV infection results in the420
epigenetic reprogramming of the host cell during malignant transformation resulting in a distinct421
HPV-induced epigenetic phenotype (20, 46). In this cohort, we found HPV infection in 23% of422
20
samples which was lower than expected although the incidence of HPV positive penile cancer423
ranges from 14%-100% and is also dependent on prior circumcision which was not recorded in424
our cohort (47). Only HPV 16 was detected in our cohort and HPV 16 represents the425
predominant subtype in PeCa and head and neck cancers (20, 45, 48). We defined a distinct,426
predominately hypomethylated, HPV 16-associated epigenetic signature. This large probe set427
was able to accurately separate an independent cohort of HNSCC cases, suggesting a lineage428
independent HPV specific epigenetic phenotype (20). However, despite the apparent synergy in429
epigenetic alterations associated with HPV infection, only 30 HPV specific MVPs were found to430
be overlapping between the two cohorts. We validated this minimal HPV signature, in431
independent HNSCC and CESC cohorts, and show it to be predictive of disease free survival in432
both HNSCC and CESC, and predictive of HPV infection in HNSCC. Interestingly when applied to433
CESC, this signature appeared to separate by HPV subtype, specifically HPV16 v HPV18/other434
HPV, supporting the postulate that we have defined a HPV16 signature. While 50% to 60% of435
CESC are associated with HPV16 infection, a further 20% are associated with HPV18 (6, 8, 49),436
this contrasts with HNSCC and PeCa in which >90% of HPV infection is HPV16. We found only437
HPV 16 in each of the two training cohorts. Although only a single CESC cohort, these data438
suggest the presence of specific HPV subtype epigenetic alterations, and further suggest a439
distinct survival advantage to HPV 16 driven tumours compared to those associated with other440
high risk HPVs, such as HPV 18 (50). In future studies it will be important to elucidate the441
functional impact of differential methylation of these genes and their role in HPV subtype442
specific driven cancer development. In terms of clinical utility, this novel methylation signature443
can be tested as a strategy to stratify cases at high risk with the potential to direct multimodal444
therapy. Moreover, the encoded proteins affected by aberrant methylation may represent445
promising drug targets for innovative and more efficient cancer therapy.446
21
447
In summary, this work shows that changes in DNA methylation are a key components in penile448
cancer. We show the utility of an epigenetic signature, which has been validated on an449
independent cohort, to identify occult lymph node metastasis in PeCa with equivalent or greater450
sensitivity to methods in current clinical practice. In addition we define a PeCa specific HPV451
signature and a HPV associated host epigenetic signature which is a lineage independent452
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Figure1 – Unsupervised clustering of methylation variable positions (MVPs) in Penile610
cancer squamous cell carcinomas611
A) Hierarchical clustering of PeCa and normal tissue based on global epigenetic profiles,612
generates 3 groups: a normal (centre, green), non-HPV-associated group (right, blue) and HPV-613
associated group (left, red), B) Heat map of methylation values of the 500 most variable loci,614
showing clear separation of normal and malignant disease. The DNA-methylation (β) values are 615 
represented using a colour scale from yellow (low DNA methylation) to blue (high DNA616
methylation), C) Heatmap of beta values for significant MVPs (Methylation Variable Position)617
(n=6933) between normal and penile cancer tissue. The DNA-methylation (β) values are 618 
represented using a colour scale from yellow (low DNA methylation) to blue (high DNA619
methylation.620
621
Figure 2 – MVP canonical feature enrichment622
Assessment of MVP enrichment in canonical gene features, for both hyper- (A and B) and hypo-623
(C and D) methylated MVPs. Shows enrichment of hypermethylated MVP in promoter624
associated features (A) and CpGI (D), Hypomethylated MVP are enriched in inter-genic regions625
(IGR) (C). Genomic features with significant (P=<0.0001) enrichment are shown in red.626
627
26
Figure 3 – Epigenetic signature of local lymphatic metastasis628
Heat map for the top 500 most variably methylated loci in penile cancers shows three629
pathologically defined clusters, a hypermethylated lymph node negative (right (upper green630
bar)), lymph node positive hypomethylated group (centre (upper gold bar)) and a HPV631
associated cluster (left (lower two bars (red = 1st- HPV positive , blue = HPV negative , black = 2nd632
HPV Viral Load, High HPV (>1 copy/cell), white = low (<1copy/cell) grey, no HPV detectable). B)633
Heatmap of methylation values for 962 significant MVP between node negative (green upper634
bar), and node positive (gold upper bar).635
Figure 4 - Epigenetic genomic profiles of DMRs associated with lymph node636
metastasis637
Methylation profiles of candidate genes associated with local lymphatic metastases, for A) IRF4638
and B) FLI1. Feature annotation are taken form the Infinium methylation arrays, methylation639
values are color-coded accordingly: TSS1500, orange (1500 bp to 200 bp upstream of the640
transcription start site (TSS)); TSS200, red (200 bp upstream of the TSS); 5' untranslated region641
(UTR), yellow; gene body, blue; CpGI , black; CpGI shores, grey; and CpGI shelves, light grey.642
Regions defined as Differentially Methylated Regions (DMRs) are highlighted by upper purple643
bars. Intermarker distances are not to genomic scale. C) ROC curve for the accuracy of lymph644
node metastasis using the QMSP epi-signature in a 50 case validation cohort.645
Figure 5 – PeCa HPV induced epigenetic signature646
A) Heat map of significant MVP (p<0.01) between HPV positive and HPV negative PeCa. HPV647
positive samples show a significantly lower methylation profile than HPV negative disease. B,C)648
Methylation profiles of candidate genes epigenetically deregulated during HPV tumorigenic649
transformation. Comparison of DMR profiles across canonical features for HPV associated PeCa650
(green) and non-HPV associated PeCa (red), for candidate epigenetically regulated genes651
27
involved in the HPV driven penile cancer ((B)GPX5 and (C)GRAMD4). Profiles show Feature652
annotation is as provided by BeadChip, and methylation values are colour-coded accordingly:653
orange = TSS1500, (1500 bp to 200 bp upstream of the transcription start site (TSS)); red =654
TSS200 (200 bp upstream of the TSS,); yellow = 5' untranslated region (UTR), blue = gene body;655
black = CpG islands,; darker grey = CpG shores,; and light grey = CpG shelves656
Figure 6 - Analysis of HPV epi-signature in independent HNSC and CESC657
A) Heatmap of 310 TCGA HNSCC samples showing the methylation of the 30 probe set classifier .658
Showing the epi-signature predicted HPV status (Positive – red, Negative –blue), Actual HPV659
status, HPV 16 positive (red), HPV negative (blue) .B) Kaplan–Meier curve showing for HNSC epi-660
signature positive (red) and epi-sganture negative (Blue).C) Heatmap of 136 CESC samples661
showing the methylation of the epi-siganutre loci. Showing the epi-signature predicted HPV662
status (Positive – red, Negative –blue), Actual HPV status, HPV 16 positive (red) samples663
containing other HPV subtypes (green), comparison of HPV sub type, HPV 16 (red), HPV18664
(green) and other HPV (purple). D) Kaplan–Meier curve showing for CESC epi-signature positive665
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HPV type 16 E6 forward primer 5'-TCAGGACCCACAGGAGCG-3'
HPV type 16 E6 reverse primer 5'-CCTCACGTCGCAGTAACTGTTG-3'




GAPDH Forward primer 5'- GGAGTCAACGGATTTGGTCGTA -3'
GAPDH Reverse primer 5'- GGCAACAATATCCACTTTACCAGAGT -3'




Supplementary Figure 1. Proportion of MVPs in penile cancers. A) Showing the proportion of hypermethylated and hypomethylated MVPs,B) Proportion of




























Propotion of Hypermethylated MVP
Feature
Supplementary Figure 2. Heatmap of 6 HNSCC cell lines (in duplicate) showing the methylation of the 30 probe set HPV classifier . Showing the epi-signature
predicted HPV status (Positive – red, Negative –blue), Actual HPV status, HPV 16 positive (red), HPV negative (blue)
Supplementary Figure 3. Methylation profiles of PeCa (green) and normal penile tissue (red) across canonical gene structure for A)FLT1, B)FLT3 C) FLT4 and
D) PDCD1. TSS1500, orange (1500 bp to 200 bp upstream of the transcription start site (TSS)); TSS200, red (200 bp upstream of the TSS); 5' untranslated
region (UTR), yellow; gene body, blue; CpGI , black; CpGI shores, grey; and CpGI shelves, light grey. Intermarker distances are not to genomic scale
Supplementary Figure 4. Comparison of DMR profiles across canonical features for PeCa (green) and normal squamous epithelium (red), for three candidate
epigenetically regulated genes involved in the development of penile cancer (AR &CDO1). Feature annotation are taken form the Infinium
methylation arrays, methylation values are color-coded accordingly: TSS1500, orange (1500 bp to 200 bp upstream of the transcription start site (TSS));
TSS200, red (200 bp upstream of the TSS); 5' untranslated region (UTR), yellow; gene body, blue; CpGI , black; CpGI shores, grey; and CpGI shelves, light grey.
Differentially methylated regions are highlighted by upper purple bars. Intermarker distances are not to genomic scale.
Comparison of gene expression between PeCa and matched normal tissue. For C) Androgen Receptor (AR), D) CDO1. Expression is
















































Supplementary Figure 5. A) Receiver Operator Curve (ROC), for the accuracy of the epigenetic lymph node prediction signature in cross validation.
B) Examples of FLI1 and IRX4 immunohistochemical staining of a PeCa TMA, in samples showing either methylation.. Methylation profiles of candidate
genes associated with local lymphatic metastases, for C) HMX3, D) PPP2R5C, . Feature annotation are taken form the Infinium methylation arrays,
methylation values are color-coded accordingly: TSS1500, orange (1500 bp to 200 bp upstream of the transcription start site (TSS)); TSS200, red (200 bp
upstream of the TSS); 5' untranslated region (UTR), yellow; gene body, blue; CpGI , black; CpGI shores, grey; and CpGI shelves, light grey. Regions defined as
Differentially Methylated Regions (DMRs) are highlighted by upper purple bars. Intermarker distances are not to genomic scale.
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Supplementary Figure 6. Heatmap of 6 HNSCC cell lines (in duplicate) showing the methylation of the 30 probe set HPV classifier . Showing the epi-signature
predicted HPV status (Positive – red, Negative –blue), Actual HPV status, HPV 16 positive (red), HPV negative (blue)
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GAPDH Forward primer 5'- GGAGTCAACGGATTTGGTCGTA -3'
GAPDH Reverse primer 5'- GGCAACAATATCCACTTTACCAGAGT -3'




Supplementary Figure 1. Proportion of MVPs in penile cancers. A) Showing the proportion of hypermethylated and hypomethylated MVPs,B) Proportion of
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Supplementary Figure 2. Methylation profiles of PeCa (green) and normal penile tissue (red) across canonical gene structure for A)FLT1, B)FLT3 C) FLT4 and
D) PDCD1. TSS1500, orange (1500 bp to 200 bp upstream of the transcription start site (TSS)); TSS200, red (200 bp upstream of the TSS); 5' untranslated
region (UTR), yellow; gene body, blue; CpGI , black; CpGI shores, grey; and CpGI shelves, light grey. Intermarker distances are not to genomic scale
Supplementary Figure 3. Comparison of DMR profiles across canonical features for PeCa (green) and normal squamous epithelium (red), for three candidate
epigenetically regulated genes involved in the development of penile cancer (AR &CDO1). Feature annotation are taken form the Infinium
methylation arrays, methylation values are color-coded accordingly: TSS1500, orange (1500 bp to 200 bp upstream of the transcription start site (TSS));
TSS200, red (200 bp upstream of the TSS); 5' untranslated region (UTR), yellow; gene body, blue; CpGI , black; CpGI shores, grey; and CpGI shelves, light grey.
Differentially methylated regions are highlighted by upper purple bars. Intermarker distances are not to genomic scale.
Comparison of gene expression between PeCa and matched normal tissue. For C) Androgen Receptor (AR), B) CDO1. Expression is
















































Supplementary Figure 4. A) Receiver Operator Curve (ROC), for the accuracy of the epigenetic lymph node prediction signature in cross validation.
B) Examples of FLI1 and IRX4 immunohistochemical staining of a PeCa TMA, in samples showing either methylation.. Methylation profiles of candidate
genes associated with local lymphatic metastases, for C) HMX3, D) PPP2R5C, . Feature annotation are taken form the Infinium methylation arrays,
methylation values are color-coded accordingly: TSS1500, orange (1500 bp to 200 bp upstream of the transcription start site (TSS)); TSS200, red (200 bp
upstream of the TSS); 5' untranslated region (UTR), yellow; gene body, blue; CpGI , black; CpGI shores, grey; and CpGI shelves, light grey. Regions defined as
Differentially Methylated Regions (DMRs) are highlighted by upper purple bars. Intermarker distances are not to genomic scale.
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